Hydrocortison Vuab (Hydrocortisone)

Hydrocortison Vuab is used in clinical practice for several acute and chronic conditions that benefit from glucocorticoid therapy. Typical applications include:

• Replacement therapy for adrenal insufficiency or Addison's disease.
• Management of severe allergic reactions and anaphylaxis.
• Treatment of acute inflammatory states such as asthma exacerbations, COPD flare‑ups, or rheumatoid arthritis flares.
• Support in septic shock or other forms of circulatory collapse.
• Adjunctive therapy for certain dermatologic or ophthalmic emergencies when rapid systemic effect is required.

• Hydrocortison Vuab delivers hydrocortisone, which binds to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus and interacts with glucocorticoid response elements, modulating transcription of anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines. This genomic effect reduces leukocyte migration, stabilizes lysosomal membranes, and decreases capillary permeability, resulting in systemic anti‑inflammatory and immunosuppressive actions.

Hydrocortison Vuab may cause a range of adverse reactions, most of which are dose‑dependent and related to its glucocorticoid activity.

Common

• Hyperglycemia or elevated blood glucose levels.
• Fluid retention leading to peripheral edema.
• Mild gastrointestinal discomfort or nausea.
• Transient increase in blood pressure.
• Local injection site pain or irritation.

Serious

• Severe infection or reactivation of latent infections.
• Osteoporosis or increased risk of fractures.
• Adrenal suppression with abrupt discontinuation.
• Psychiatric disturbances such as mood swings or psychosis.
• Thromboembolic events including deep vein thrombosis.

Before using Hydrocortison Vuab, clinicians should consider several safety factors to minimize risk:

• Assess for active or latent infections; avoid use in uncontrolled systemic infections.
• Evaluate blood glucose and blood pressure, especially in diabetic or hypertensive patients.
• Use the lowest effective dose for the shortest duration to reduce risk of adrenal suppression.
• Monitor bone health in patients requiring long‑term therapy.
• Caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
• Consider potential effects on wound healing and surgical recovery.
• Discuss pregnancy and lactation status, as safety data are limited.

Hydrocortison Vuab can interact with other medications, altering efficacy or increasing toxicity.

Avoid

• Concurrent use of potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone levels.
• Live vaccines, which may be less effective or cause infection.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can increase risk of gastrointestinal bleeding.
• Anticoagulants, as glucocorticoids may enhance anticoagulant effects.
• Diabetic medications, due to potential hyperglycemia.
• Antihypertensive agents, because fluid retention may counteract blood pressure control.
• Other immunosuppressants, which may compound infection risk.